Pura Vida Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pura Vida Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-175,356	Closed	-$13.5M	–	217
2022 Q1	$13.5M	Buy	175,356 +5,146	+3%	+$431K	0.44%	57
2021 Q4	$15M	Buy	+170,210	New	+$14M	0.54%	46
2020 Q4	–	Sell	-10,000	Closed	-$761K	–	185
2020 Q3	$761K	Buy	+10,000	New	+$1.01M	0.04%	136
2018 Q2	–	Sell	-43,700	Closed	-$3.54M	–	96
2018 Q1	$3.54M	Hold	43,700	–	–	2.09%	17
2017 Q4	$3.9M	Buy	+43,700	New	+$3.8M	1.63%	24

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Pura Vida Investments's BMRN Position: Q2 2022 in Review

Pura Vida Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 175,356 shares — an estimated $13.5M sold.

Pura Vida Investments first reported a position in BMRN in Q4 2017 and held it in 5 quarters. The position peaked at $15M in Q4 2021. 543 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Pura Vida Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Pura Vida Investments sold 175,356 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $13.5M.
Pura Vida Investments first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Pura Vida Investments's BioMarin Pharmaceuticals position peaked at $15M in Q4 2021.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.